Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation

被引：0
|
作者：
Fahad Shaikh
Lachlan B. Pasch
Phillip J. Newton
Beata V. Bajorek
Caleb Ferguson
机构：
[1] University of Technology Sydney,Discipline of Pharmacy, Graduate School of Health
[2] Western Sydney Nursing and Midwifery Research Centre,undefined
[3] Western Sydney Local Health District and Western Sydney University,undefined
[4] Blacktown Clinical and Research School,undefined
[5] Blacktown Hospital,undefined
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Atrial fibrillation; Multimorbidity; Polypharmacy; Anticoagulation; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Management of polypharmacy in older people with multimorbidity
    Hoffmann, Ute
    INNERE MEDIZIN, 2024, 65 (01): : 9 - 16
  • [42] MULTIMORBIDITY AND POLYPHARMACY IN ELDERLY RESIDENTS IN THE COMMUNITY
    Lopes de Andrade Bongiovani, LucimaraFatima
    Miotto, Natalia
    da Rocha Restelatto, Marcia Terezinha
    Cetolin, Sirlei Favero
    Beltrame, Vilma
    REVISTA DE PESQUISA-CUIDADO E FUNDAMENTAL ONLINE, 2021, 13 : 349 - 354
  • [43] Obesity and Atrial Fibrillation: Should We Screen for Atrial Fibrillation in Obese Individuals? A Comprehensive Review
    Ghattas, Kyrillos N.
    Ilyas, Shahbakht
    Al-Refai, Reham
    Maharjan, Reeju
    Bustamante, Liliana Diaz
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [44] Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
    Zheng, Yuxiang
    Li, Siyuan
    Liu, Xiao
    Lip, Gregory Y. H.
    Guo, Linjuan
    Zhu, Wengen
    THROMBOSIS AND HAEMOSTASIS, 2025, 125 (02) : 166 - 177
  • [45] Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis
    Gallagher, Celine
    Nyfort-Hansen, Karin
    Rowett, Debra
    Wong, Christopher X.
    Middeldorp, Melissa E.
    Mahajan, Rajiv
    Lau, Dennis H.
    Sanders, Prashanthan
    Hendriks, Jeroen M.
    OPEN HEART, 2020, 7 (01):
  • [46] Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial
    Proietti, Marco
    Raparelli, Valeria
    Olshansky, Brian
    Lip, Gregory Y. H.
    CLINICAL RESEARCH IN CARDIOLOGY, 2016, 105 (05) : 412 - 420
  • [47] Addressing Comorbidities in Heart Failure Hypertension, Atrial Fibrillation, and Diabetes
    Bavishi, Aakash
    Patel, Ravi B.
    HEART FAILURE CLINICS, 2020, 16 (04) : 441 - 456
  • [48] Addressing Disparities in Stroke Prevention for Atrial Fibrillation: Educational Opportunities
    Karcher, Rachel
    Berman, Adam E.
    Gross, Hartmut
    Hess, David C.
    Jauch, Edward C.
    Viser, Paul E.
    Solenski, Nina J.
    Wolf, Andrew M. D.
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2016, 31 (04) : 337 - 348
  • [49] Addressing the Controversy of Rate Versus Rhythm Control in Atrial Fibrillation
    Contractor, Tahmeed
    Levin, Vadim
    Desai, Ravi
    Marchlinski, Francis E.
    POSTGRADUATE MEDICINE, 2013, 125 (05) : 7 - 18
  • [50] Evolving developments in the therapeutics of atrial fibrillation: Addressing an unmet need
    Nattel, Stanley
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2008, 52 (01) : 1 - 3
12345